NASDAQ:HALO • US40637H1095
Past quarterly earnings results for HALOZYME THERAPEUTICS INC (HALO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.24 | 2.24 | -110.70% | -119.05% | 451.767M | 446.74M | 1.13% | 51.60% |
| Q3 2025 | 1.72 | 1.66 | 3.56% | 35.43% | 354.264M | 346.72M | 2.18% | 22.12% |
| Q2 2025 | 1.54 | 1.29 | 19.26% | 69.23% | 325.719M | 291.64M | 11.69% | 40.79% |
| Q1 2025 | 1.11 | 0.97 | 14.79% | 40.51% | 264.861M | 234.78M | 12.81% | 35.22% |
| Q4 2024 | 1.26 | 1.18 | 6.64% | 53.66% | 298.008M | 294.01M | 1.36% | 29.55% |
| Q3 2024 | 1.27 | 1.00 | 26.79% | 69.33% | 290.084M | 256.08M | 13.28% | 34.28% |
| Q2 2024 | 0.91 | 0.77 | 17.68% | 22.97% | 231.353M | 209.04M | 10.67% | 4.67% |
| Q1 2024 | 0.79 | 0.71 | 11.44% | 68.09% | 195.879M | 203.77M | -3.87% | 20.81% |
| Q4 2023 | 0.82 | 0.84 | -2.55% | 70.83% | 230.039M | 235.76M | -2.43% | 26.74% |
| Q3 2023 | 0.75 | 0.72 | 3.96% | 1.35% | 216.033M | 220.43M | -1.99% | 3.37% |
| Q2 2023 | 0.74 | 0.64 | 15.31% | 39.62% | 221.038M | 203.95M | 8.38% | 45.04% |
| Q1 2023 | 0.47 | 0.49 | -3.40% | - | 162.143M | 179.02M | -9.43% | 38.23% |
| Q4 2022 | 0.48 | 0.48 | 1.02% | 14.29% | 181.5M | 195.9M | -7.35% | 77.94% |
| Q3 2022 | 0.74 | 0.52 | 41.37% | 45.10% | 209M | 194.93M | 7.22% | 80.48% |
| Q2 2022 | 0.53 | 0.51 | 3.58% | -14.52% | 152.4M | 141.56M | 7.66% | 11.65% |
| Q1 2022 | 0.47 | 0.50 | -5.96% | 27.03% | 117.3M | 130.82M | -10.33% | 31.80% |
| Q4 2021 | 0.42 | 0.41 | 1.36% | -16.00% | 102M | 102.33M | -0.32% | -16.19% |
| Q3 2021 | 0.51 | 0.43 | 18.20% | 104.00% | 115.8M | 107.74M | 7.48% | 77.34% |
| Q2 2021 | 0.62 | 0.42 | 47.85% | 226.32% | 136.5M | 106.13M | 28.62% | 147.28% |
| Q1 2021 | 0.37 | 0.32 | 14.15% | 1,025.00% | 89M | 86.576M | 2.80% | 250.39% |
| Q4 2020 | 0.50 | 0.54 | -8.15% | - | 121.7M | 122.57M | -0.71% | - |
| Q3 2020 | 0.25 | 0.20 | 25.88% | - | 65.3M | 62.12M | 5.12% | - |
| Q2 2020 | 0.19 | 0.25 | -24.33% | - | 55.2M | 68.01M | -18.84% | - |
| Q1 2020 | -0.04 | -0.02 | -89.17% | - | 25.4M | 43.821M | -42.04% | - |
Notes
HALOZYME THERAPEUTICS INC (HALO) last reported earnings on 2/17/2026.
HALOZYME THERAPEUTICS INC (HALO) missed EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, HALOZYME THERAPEUTICS INC (HALO) has beaten EPS estimates in 3 out of 4 releases.